PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients

Summary

From this randomized controlled study, we aim to: A.Do do cardiovascular risk stratification of renal transplant recipients who are followed up in Hamed Al-Essa organ transplant center of Kuwait. B. To compare the effectiveness of a PCSK9 inhibitor plus maximum tolerated statin therapy vs. maximum tolerated statin therapy alone in the reduction of major cardiovascular events among renal transplant recipients with cardiovascular disease. C. To compare the effectiveness of a PCSK9 inhibitor plus maximum tolerated statin therapy vs. maximum tolerated statin therapy alone in terms of LDL-C-lowering, muscle symptoms, and quality of life. D. To compare patient adherence to the different treatment protocols.

Timeline

Start

2018-05-01

Primary completion

2020-05-01

Completion

2020-05-01

Drugs

Indications

No indication recorded.